Shenzhen Zhongke Weiguang Medical Device Technology

About Shenzhen Zhongke Weiguang Medical Device Technology

Shenzhen Zhongke Weiguang Medical Device Technology Co., Ltd., operating as Vivolight, is a medical technology firm established in 2012. The company was founded by Zhu Rui (Ray Zhu), who serves as CEO and holds both a bachelor's and a master's degree from Tsinghua University. The impetus for the company's creation came from a personal experience in 2009 when Zhu's mother faced a delayed diagnosis due to unclear medical imaging, inspiring him to apply his research in Optical Coherence Tomography (OCT) to create more precise diagnostic tools. Initially incubated by the Xi'an Institute of Optics and Precision Mechanics of the Chinese Academy of Sciences, Vivolight has established its headquarters in Shenzhen with a significant R&D center in Xi'an.

Vivolight focuses on the development, manufacturing, and sale of minimally invasive interventional medical devices that utilize laser and optical imaging technology. The company serves hospitals and clinical settings, with its products now distributed in over 90 countries. Its business model revolves around the direct sale of these high-tech medical devices and associated single-use consumables, such as imaging catheters. The company has secured significant funding through multiple rounds, including a Series B in March 2024 and Series D1 and D2 rounds in 2022, to fuel product development and global expansion.

The company's core technology platform integrates laser diagnostics, fiber-optic catheters, and image processing to create a 'diagnosis and treatment integrated' system. Its flagship product line is the Cornaris® series of intravascular Optical Coherence Tomography (OCT) systems (P60, P80, Mobile, and Zero), which provide high-resolution, cross-sectional images of blood vessels to guide cardiovascular interventions like stent placement. These systems offer superior resolution compared to older technologies, allowing for more precise treatment and assessment of conditions like Chronic Total Occlusion (CTO) and In-Stent Restenosis (ISR). In April 2025, Vivolight's Cornaris P80 OCT system and LumenCross F2 imaging catheter received FDA 510(k) clearance, a key milestone for entering the U.S. market and other regions that recognize FDA approval. Beyond cardiovascular applications, the company's portfolio includes the VEINCAS series of projection vein finders and is developing laser ablation systems for various vascular fields.